Cancer and blood coagulation
Cancer and blood coagulation
复制标题
DOI：
10.1007/s00018-005-5570-9
复制
发表时间：
2006-05-01
影响因子：
8
通讯作者：
Medico, E
中科院分区：
文献类型：
--
作者：
Boccaccio, C;Medico, E
在人类患者中，凝血功能障碍往往与癌症有关，甚至在癌症的早期阶段也是如此。最近，体外和体内实验模型表明，癌基因的表达，或肿瘤抑制基因的失活，上调了控制凝血的基因。这些研究表明，凝血的激活，导致瘤周纤维蛋白沉积，在癌症的发展中起着重要作用。纤维蛋白确实可以形成临时基质，支持肿瘤组织和血管的侵袭性生长。因此，干扰凝血可以被认为是癌症多方面治疗方法的一部分。
In human patients, blood coagulation disorders often associate with cancer, even in its early stages. Recently, in vitro and in vivo experimental models have shown that oncogene expression, or inactivation of tumour suppressor genes, upregulate genes that control blood coagulation. These studies suggest that activation of blood clotting, leading to peritumoral fibrin deposition, is instrumental in cancer development. Fibrin can indeed build up a provisional matrix, supporting the invasive growth of neoplastic tissues and blood vessels. Interference with blood coagulation can thus be considered as part of a multifaceted therapeutic approach to cancer.